IL113772A0 - Mucosal administration of pneumococcal antigens - Google Patents

Mucosal administration of pneumococcal antigens

Info

Publication number
IL113772A0
IL113772A0 IL11377295A IL11377295A IL113772A0 IL 113772 A0 IL113772 A0 IL 113772A0 IL 11377295 A IL11377295 A IL 11377295A IL 11377295 A IL11377295 A IL 11377295A IL 113772 A0 IL113772 A0 IL 113772A0
Authority
IL
Israel
Prior art keywords
mucosal administration
pneumococci
pneumococcal antigens
against pneumococcal
whole
Prior art date
Application number
IL11377295A
Other languages
English (en)
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/246,636 external-priority patent/US5965141A/en
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Publication of IL113772A0 publication Critical patent/IL113772A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL11377295A 1994-05-20 1995-05-18 Mucosal administration of pneumococcal antigens IL113772A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/246,636 US5965141A (en) 1991-02-15 1994-05-20 Epitopic regions of pneumococcal surface protein a
US08/312,949 US6027734A (en) 1991-02-15 1994-09-30 Mucosal administration of pneumococcal antigens

Publications (1)

Publication Number Publication Date
IL113772A0 true IL113772A0 (en) 1995-08-31

Family

ID=26938117

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11377295A IL113772A0 (en) 1994-05-20 1995-05-18 Mucosal administration of pneumococcal antigens

Country Status (13)

Country Link
US (1) US6027734A (de)
EP (1) EP0682950B1 (de)
JP (1) JP2747435B2 (de)
AT (1) ATE182270T1 (de)
AU (1) AU698724B2 (de)
CA (1) CA2149703A1 (de)
DE (1) DE69510858T2 (de)
DK (1) DK0682950T3 (de)
ES (1) ES2135663T3 (de)
FI (1) FI952445A (de)
GR (1) GR3031491T3 (de)
IL (1) IL113772A0 (de)
NO (1) NO951982L (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0871479A2 (de) * 1995-06-02 1998-10-21 The Uab Research Foundation Orale verabreichung von pneumokokken-antigenen
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
CA2325340A1 (en) * 1998-04-07 1999-10-14 Medimmune, Inc. Derivatives of pneumococcal choline binding proteins for vaccines
US20010016200A1 (en) * 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
AU2001224429A1 (en) * 2000-09-29 2002-04-15 Genomics Collaborative, Inc. Methods of diagnosing community acquired pneumonia (cap) and predisposition or susceptibility for cap and associated septic shock through detection of gene polymorphisms
JP4304077B2 (ja) * 2002-02-13 2009-07-29 イミュノロジー ラボラトリーズ インコーポレイテッド 微生物感染の処置のための組成物および方法
WO2005021713A2 (en) 2003-06-20 2005-03-10 Protein Sciences Corporation Vectors expressing sars immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
KR20110110825A (ko) * 2003-11-10 2011-10-07 유에이비 리서치 파운데이션 세균의 운반 및 ｃｎｓ 침입을 감소시키기 위한 조성물 및 이를 이용한 방법
US8252546B2 (en) * 2006-08-17 2012-08-28 The Uab Research Foundation Diagnosing pneumococcal pneumonia
US8329195B2 (en) * 2007-05-23 2012-12-11 The Uab Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
WO2014045621A1 (ja) 2012-09-19 2014-03-27 国立大学法人大阪大学 肺炎球菌表面タンパク質ａを含む肺炎球菌ワクチン
US11053532B2 (en) 2017-04-19 2021-07-06 CAP Diagnostics, LLC Methods for treating polymicrobial infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6444889U (de) * 1987-09-14 1989-03-17
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
CA2104014C (en) * 1991-02-15 2000-05-02 David E. Briles Structural gene of pneumococcal protein
WO1994014318A1 (en) * 1992-12-24 1994-07-07 Medimmune, Inc. Method of protection against streptococcus pneumoniae with transformed mycobacteria
CA2116261A1 (en) * 1993-04-20 1994-10-21 David E. Briles Epitopic regions of pneumococcal surface protein a

Also Published As

Publication number Publication date
FI952445A0 (fi) 1995-05-19
EP0682950B1 (de) 1999-07-21
AU698724B2 (en) 1998-11-05
DK0682950T3 (da) 1999-11-29
DE69510858D1 (de) 1999-08-26
EP0682950A1 (de) 1995-11-22
CA2149703A1 (en) 1995-11-21
JP2747435B2 (ja) 1998-05-06
DE69510858T2 (de) 2000-04-13
US6027734A (en) 2000-02-22
ES2135663T3 (es) 1999-11-01
JPH0840927A (ja) 1996-02-13
AU2015095A (en) 1995-11-30
GR3031491T3 (en) 2000-01-31
FI952445A (fi) 1995-11-21
NO951982L (no) 1995-11-21
ATE182270T1 (de) 1999-08-15
NO951982D0 (no) 1995-05-19

Similar Documents

Publication Publication Date Title
IL113772A0 (en) Mucosal administration of pneumococcal antigens
IL145982A0 (en) Vaccines
CA2243755A1 (en) Streptococcal c5a peptidase vaccine
IL87608A0 (en) Recombinant dna-derived bordetella toxin subunit analogs
CA2089552A1 (en) Inactivated mycoplasma hyopneumoniae bacterin and method of use thereof
IL115047A (en) Immunogenic conjugates comprising pneumococcal polysaccharide and recombinant pneumolysin, vaccines comprising such conjugates and use of such vaccines in the manufacture of medicaments for immunizing against pneumococcal infections
BRPI9700768B1 (pt) vacina viva para combater infecção por streptococcus em cavalos.
CA2188284A1 (en) Group a streptococcal polysaccharide immunogenic compositions and methods
LU91153I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine et de polyoside capsulaire d'Haemophilus influenzae type b.
NZ287385A (en) Antigenic preparation comprising the catalase of helicobacter bacteria and vaccines used to treat helicobacter infection
CA2022420A1 (en) Escherichia coli vaccine
ATE274919T1 (de) Feste dispergierende impfstoffe-zusammensetzung zur oralen verabreichung
CA2154063A1 (en) Treatment of h. pylori associated gastroduodenal disease
CA2271008A1 (en) Acellular pertussis vaccine with diphtheria- and tetanus-toxoids
HUP9801266A2 (hu) Multimer, rekombináns ureázvakcina
WO2003000204A8 (en) Multivalent mycoplasma bacterin
CA2330313A1 (en) Immunization against and treatment for infection by h.pylori
WO1996039113A3 (en) Oral administration of pneumococcal antigens
WO2000062802A3 (en) Vaccine comprising rsv antigen and cpg oligonucleotide
WO2003032917A3 (en) Hookworm vaccine
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
CA2388054A1 (en) Compositions and methods for stimulating an immune response against infectious agents
Mauro et al. Further observations on a dipheheria-tetanus vaccine adult type.
Renault Study of ribosomal vaccine against experimental staphylococcal skin infection in rabbit.
Bardina et al. Features of present course of epidemic process of diphtheria infection.